Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Hepatology. 2013 Aug 6;58(4):1215–1224. doi: 10.1002/hep.26387

Table 2.

Estimated global and regional prevalence of hepatitis C virus antibodies among prison detainees

N included sources % of general detainee populations with HCV antibody prevalence data Pooled HCV antibody prevalence (95% CI) Prison detainee population Estimated number of HCV antibody positive prison detainees
Low Mid High
Sub-Saharan Africa 4 8 16 (7, 26) 785,00 55,000 125,500 204,000
Western Europe 39 92 30 (26, 34) 478,500 124,500 143,500 162,500
Eastern Europe 6 16 22 (14, 31) 1,199,000 168,000 263,500 371,500
Latin America 12 68 14 (8, 19) 1,161,000 93,000 162,500 220,500
Australasia 9 78 35 (28, 43) 37,500 10,500 13,000 16,000
North America 14 100 29 (24, 34) 2,306,00 553,500 668,500 784,000
South Asia 4 56 8 (4, 11) 827,000 33,000 66,000 91,000
Middle East and North Africa 1 1 3 (1, 5) 491,500 5,000 14,500 24,500
East and Southeast Asia 2 8 25 (13, 38) 2,552,000 332,000 638,000 970,000
Central Asia 1 8 38 (32, 43) 123,500 39,500 47,000 53,000
Pacific Islands - 0 - 8,500 - - -
Caribbean - 0 - 34,000 - - -
Extrapolated global 92 45 26 (23, 29) 10,004,000 1,423,000 2,154,500 2,910,000

Note: ‘Prison’ includes all institutions for adults charged with, awaiting trial or sentenced for a criminal offence. It does not include compulsory detoxification centres. All figures rounded to the nearest 500 people. Extrapolated global figure totalled from regional estimates prior to rounding. “-“ indicates there were no data on HCV prevalence located in this region. These regions were included in the extrapolated global estimate by applying the total estimated HCV prevalence to the prison detainee population for these regions. Data on detainee populations obtained from the World Prison Brief of the International Centre for Prison Studies (http://www.prisonstudies.org/).